GHR and familial pancreatic carcinoma: Focused preclinical studies with human PDX models with dose-titration of combinations of GHRAs and selected antineoplastic agents and subsequent carefully designed human clinical trials are needed to validate the transformative prognostic potential of targeting GHR in pancreatic cancer.